Table 1. Demographic Characteristics Associated With Tests Among Individuals With at Least 2 Doses of the BNT162b2 Vaccine Who Were Tested August 1-October 4, 2021a.
| Characteristics | Individuals receiving 2 doses (n = 227 380) | Individuals receiving 3 doses (n = 272 852) |
|---|---|---|
| Age, mean (SD), y | 53.0 (10.6) | 59.0 (12.5) |
| Age group, y | ||
| 40-49 | 106 264 (46.7) | 71 143 (26.1) |
| 50-59 | 72 752 (32.0) | 80 839 (29.6) |
| 60-69 | 27 696 (12.2) | 64 604 (23.7) |
| 70-79 | 13 773 (6.1) | 35 689 (13.1) |
| ≥80 | 6895 (3.0) | 20 577 (7.5) |
| Sex | ||
| Male | 97 058 (42.7) | 127 281 (46.6) |
| Female | 130 322 (57.3) | 145 571 (53.4) |
| SES Index, mean (SD) (range, 1-10) | 6.80 (1.85) | 7.04 (1.84) |
| Comorbidities | ||
| Cardiovascular disease | 3247 (1.4) | 7497 (2.7) |
| Obesity (BMI ≥30) | 49 901 (21.9) | 65 383 (24.0) |
| Immunosuppression | 6028 (2.7) | 9314 (3.4) |
| Diabetes | 19 993 (8.8) | 38 733 (14.2) |
| Chronic kidney disease | 23 182 (10.2) | 52 048 (19.1) |
| Hypertension | 49 012 (21.6) | 89 696 (32.9) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); SES, socioeconomic status.
a
Data are related to the number of tests; individuals can be counted more than once for these calculations.